A5031120695- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Salivary Gland Disorders and Functions
- Protein Degradation and Inhibitors
- Platelet Disorders and Treatments
- Advanced Proteomics Techniques and Applications
- Intramuscular injections and effects
- Heparin-Induced Thrombocytopenia and Thrombosis
- Lymphoma Diagnosis and Treatment
- Endoplasmic Reticulum Stress and Disease
- Mesenchymal stem cell research
- Blood donation and transfusion practices
- Hospital Admissions and Outcomes
- Nuclear Engineering Thermal-Hydraulics
- Cardiac, Anesthesia and Surgical Outcomes
- Protease and Inhibitor Mechanisms
- Combustion and Detonation Processes
- Trauma and Emergency Care Studies
- Hemoglobinopathies and Related Disorders
- Colorectal Cancer Treatments and Studies
- Neonatal Respiratory Health Research
- Colorectal Cancer Surgical Treatments
- Emergency and Acute Care Studies
St. James's Hospital
2021
Tallaght University Hospital
2014-2021
Mater Misericordiae University Hospital
2015-2020
National Institute for Bioprocessing Research and Training
2016-2019
Dublin City University
2016-2019
St. Vincent's University Hospital
2014
Trinity College Dublin
2014
Children's Health Ireland at Crumlin
2012
Our Lady's Hospital
2012
Abstract Background Pelvic exenteration for locally recurrent rectal cancer (LRRC) is associated with variable outcomes, the majority of data from single-centre series. This study analysed an international collaboration to determine robust parameters that could inform clinical decision-making. Methods Anonymized on patients who had pelvic LRRC between 2004 and 2014 were accrued 27 specialist centres. The primary endpoint was survival. impact resection margin, bone resection, node status use...
Summary Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a novel entity that emerged in March 2021 following reports of unusual thrombosis after ChAdOx1 nCoV‐19, (AstraZeneca) vaccination. Following the recognition this syndrome, multiple consensus guidelines have been released to risk stratify patients presenting with possible symptoms nCoV‐19 All rapidly identify VITT complete triad thrombocytopenia, and elevated D‐dimers However, earlier associated symptoms, clinical...
The pathological progression from benign monoclonal gammopathy of undetermined significance (MGUS) to smoldering myeloma (SMM) and finally active (MM) is poorly understood. Abnormal immunoglobulin G (IgG) glycosylation in has been reported. Using a glycomic platform composed hydrophilic interaction UPLC, exoglycosidase digestions, weak anion-exchange chromatography, mass spectrometry, polyclonal IgG N-glycosylation profiles 35 patients [MGUS (n = 8), SMM 5), MM complete-response (CR)...
Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. measured C-terminal telopeptide type I collagen (CTX-1), Procollagen 1 N Propeptide (P1NP) 86 MM patients 26 controls. CTX-1 was higher newly diagnosed compared to control, remission (P < 0·05), decreased following treatment. In the setting relapse, rise greater than calculated least significant change (LSC)...
Multiple Myeloma (MM), the second most common lymphoid cancer worldwide, is characterised by uninhibited proliferation of terminally differentiated B-lymphocytes. Leading to The diagnosis typically requires presence a monoclonal protein (M protein) and demonstration CRAB features (hypercalcemia, renal impairment, anaemia bone lesions). MM considered incurable as, due serial clonal evolution, vast majority patients succumb treatment-refractory disease. MGUS (Monoclonal Gammopathy Unknown...
Multiple myeloma is a malignant plasma cell disorder characterized by abnormal proliferation of clonal cells in the bone marrow microenvironment. Involvement central nervous system rare extramedullary manifestation multiple myeloma, occurring approximately 1% patients and confers poor prognosis with median overall survival 2-4 months [1, 2]. CNS defined presence cerebrospinal fluid (CSF) and/or leptomeningeal, dura mater, or intraparenchymatous involvement [3]. While novel therapies such as...